Amphastar Pharmaceuticals, Inc. (AMPH)
| Market Cap | 977.10M |
| Revenue (ttm) | 719.89M |
| Net Income (ttm) | 98.09M |
| Shares Out | 44.53M |
| EPS (ttm) | 2.03 |
| PE Ratio | 10.78 |
| Forward PE | 6.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 132,012 |
| Open | 21.71 |
| Previous Close | 21.65 |
| Day's Range | 21.56 - 22.03 |
| 52-Week Range | 17.03 - 31.26 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 28.38 (+29.35%) |
| Earnings Date | May 7, 2026 |
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the preven... [Read more]
Financial Performance
In 2025, Amphastar Pharmaceuticals's revenue was $719.89 million, a decrease of -1.65% compared to the previous year's $731.97 million. Earnings were $98.09 million, a decrease of -38.51%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price target is $28.38, which is an increase of 29.35% from the latest price.
News
Amphastar Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
Strong growth in 2025 was driven by Baqsimi and Primatene Mist, with new launches and a robust pipeline supporting mid to high single-digit revenue growth for 2026. Strategic product discontinuations and collaborations are improving margins and market reach, while disciplined business development and a solid balance sheet position the company for further expansion.
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulato...
Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 4, 2026 / announced today that Bill Peters, CFO, and Dan Dischner, SVP of Corp. Communication, will be presenting at the Barclays 28th Annual Global Heal...
Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw resilient growth in BAQSIMI and new FDA approvals, offset by legacy product declines and margin pressures. 2026 guidance calls for mid-to-high single-digit revenue growth, driven by new launches and pipeline expansion, with continued investment in R&D and manufacturing.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or...
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre...
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December...
Amphastar Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
A fully integrated model and dual growth strategy drive a shift toward proprietary and biosimilar products, with significant R&D investment fueling a robust pipeline in oncology, ophthalmology, and endocrinology. Key growth is expected from Baqsimi, Primatene Mist, and upcoming launches, while strategic market exits and targeted acquisitions support profitability.
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, In...
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...
Amphastar Announces FDA Approval for Teriparatide Injection
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre...
Amphastar Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is shifting its pipeline toward proprietary products, aiming for 50% by 2026, with key growth expected from AMP-007, Baqsimi, and new biosimilars. Baqsimi is positioned for significant expansion, supported by strong patent protection and commercial efforts.
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical...
Amphastar Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Shifting focus to proprietary and biosimilar products, double-digit growth in Baqsimi and Primatene Mist is expected to continue into 2026. Key pipeline launches, especially AMP-007, are set to drive revenue and margin expansion, supported by strong liquidity.
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration...
Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw stable revenues at $191.8M, with strong growth from BAQSIMI and Primatene MIST offset by declines in other products. The pipeline expanded with three novel peptides, and iron sucrose injection launched. Guidance remains for flat 2025 revenue and growth in 2026.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025 GAAP net income of $17.4 million, or $0.37 per share, for the third quarter Adjusted non-GAAP net income of $44.7 m...
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September ...
Amphastar Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Strong double-digit growth in Baqsimi and Primatene Mist, new launches like iron sucrose, and a robust proprietary pipeline are set to drive margin expansion and profitability. Strategic diversification into oncology and ophthalmology, plus cost controls, position the company for sustained growth.
Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be par...
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.'s AMPH Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, an...
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc...
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with chr...
Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2025
Q2 2025 saw revenues of $174.4M and net income of $31M, with BAQSIMI sales up 21% year-over-year. Guidance remains for flat annual sales, with margin pressure from competition and new product launches expected to offset declines.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP net income of $40.9...